BMS Makes Deeper Dent In Asia Hepatitis Market As Baraclude Moves Toward Blockbuster Status
This article was originally published in PharmAsia News
Executive Summary
BMS’ hepatitis B therapy Baraclude moves toward blockbuster status as company highlights risk of drug resistance with older treatments.